Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.
In a letter to shareholders published today (6 January), the chair of the board Dr Charmaine Gittleson, alongside non-executive director Dr Gil Price and managing director Dr James Garner, told shareholders that the company “will undertake a broad strategic review of the company’s pipeline to more comprehensively evaluate alternative sources of value within the current assets”.
The review follows negative topline results from the Phase IIb trial (NCT05938023) of avicursen in boys with non-ambulatory DMD. Announced on 18 December, the results demonstrated that the trial did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL2.0) score at week 25 compared to placebo. [Learn More about Clinical Trial]
